For example: endocrine therapy for hormone receptor-positive subtypes (e.g., tamoxifen, aromatase inhibitors); HER2-targeted therapy for HER2-positive cancers (e.g., trastuzumab, pertuzumab); and immune checkpoint inhibitors (e.g., atezolizumab) have recently been shown to have some efficacy in certain TNBC subtypes [5]. The gene discussed is ERBB2; the disease is cancer.